Clinical Trial Update: Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study evaluating TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab for color…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colorectal Cancer, Minimal Residual Disease | Phase 1 | Status: RECRUITING